INTRODUCTION

Parathyroid carcinoma is a rare endocrine malignancy, rarer when synchronous with a nonmedullary well-differentiated thyroid carcinoma. Parathyroid carcinoma (PC) accounts of 0.005% of all malignant tumors, and it is responsible for less than 1% of primary hyperparathyroidism.

The initial manifestation of parathyroid carcinoma is usually quite acute, and the serum calcium and parathyroid hormone (PTH) levels are often higher than with parathyroid adenoma. Concurrent thyroid carcinoma in these patients is extremely rare, and to our knowledge, only a few 15 cases have been described previously in published reports. In 1974, the first case of concomitant thyroid and parathyroid disease was reported. The association
between hyperparathyroidism and nonmedullary well-differentiated thyroid carcinoma is found in 2.4%–3.7% of hyperparathyroidism cases. However, coexistence of primary hyperparathyroidism due to parathyroid carcinoma with thyroid carcinoma is extremely rare. Here, we describe a patient with this uncommon presentation.

2 | CASE REPORT

A 60-year-old woman with a history of diabetes mellitus type 2, hypertension, and no family history of thyroid cancer or multiple endocrine neoplasia type 1 or 2 presented with symptoms of severe hypercalcemia (confusion, acute renal failure, dehydration). Her calcium level was at 13.83 mg/dl (reference range, 8.8–10.4) with an increased serum parathyroid hormone level 569 pg/ml (reference range 10–65) (Table 1).

Physical examination revealed a 3 cm basal cervical swelling lateralized to the left with absence of recurrent nerve palsy or cervical lymphadenopathy.

The cervical ultrasound showed a multinodular thyroid gland with 4–10 mm highly hypoechoic nodules classified as EU-TIRADS five associated with a large nodule at the upper pole of the left thyroid which measured 3 cm evoking a parathyroid mass. Technetium-99m methoxyisobutylisonitrile (MIBI) cervical and mediastinal subtraction scintigraphy scans revealed increased uptake of left polar superior area of thyroid. A dual-energy X-ray absorptiometry test performed showed no evidence osteoporosis. Blood and urine tests and calcitonin levels were normal, making multiple endocrine neoplasia type 2 very unlikely.

The patient received intravenously administered fluids and diuretics. Then, a total thyroidectomy, left parathyroidectomy, and central and lateral cervical lymph node dissection were performed in consideration of extemporaneous histological examination suggestive of a papillary microcarcinoma of the left lobe (Figure 1) and the suspicious aspect of the 4 cm parathyroid formation which was hard and adherent to the thyroid and difficult to dissect from the vascular axis (Figure 2A).

The definitive anatomopathological examination of the operative specimen showed a bifocal papillary microcarcinoma with vesicular component, with absence of central ganglion metastases. The left parathyroid gland was the site of significant multinodular hyperplasia with central nodule involvement with vascular emboli and capsular invasion (Figure 2B,C).

Considering the severity of the hypercalcemia and macroscopic appearance as well as the histological aspect, the diagnosis of parathyroid carcinoma was retained. Postoperatively, the patient was prescribed orally administered calcium and vitamin D3 and had normocalcemia in conjunction with PTH levels measured 30 pg/ml. Investigations showed no distant metastasis. Subsequently, the patient has remained normocalcemic, and the most recent serum calcium level (at 6-month postoperative follow-up) was 9 mg/dl (Table 1).

3 | DISCUSSION

Although parathyroid carcinoma is not a usual cause of primary hyperparathyroidism, its incidence is increasing due to increased incidence of diagnosed primary hyperparathyroidism. Many presenting features of parathyroid hormone-dependent hypercalcemia that should suggest the etiology of parathyroid carcinoma are shown in Table 2. The presence of some of these features in our patient, particularly the high calcium and PTH levels in serum, alert before surgery to the possibility of malignancy. After surgery, some anatomopathological features such as trabecular architecture, thick capsule, fibrous trabecular traversing the gland, nuclear atypia, and high mitotic rates should be looked for in parathyroid carcinoma, but none of these changes the diagnostic. The most definitive diagnostic criteria for parathyroid carcinoma are invasion of adjacent tissues capsular and vascular

| Laboratory values | At admission | At 6 months postoperatively | Normal range |
|-------------------|-------------|-----------------------------|--------------|
| Calcium (mg/dl)   | 13.83       | 9                           | 8.8–10.4     |
| Phosphatemia (mg/dl) | 2.28       | 2.64                        | 2.4–5        |
| Parathyroid Hormone (pg/ml) | 569       | 22                          | 10–65        |
| Albumin (g/L)     | 36          | 38                          | 35–50        |
| Magnesium(mg/dl)  | 2.2         | 2.1                         | 1.9–2.7      |
| Creatinine (μmol/L) | 158       | 88                          | 55–115       |
| 25-OH-Vitamin D (ng/ml) | 22       | 31                          | 20–40        |
| Calcitonin (pg/ml) | 1          | -                           | <5           |

TABLE 1 Laboratory findings
invasions (found in our case), involvement of regional lymph nodes, and distant metastatic lesions (not found in our case). The fibrotic pattern of the tumor invading the adjacent thyroid tissue in the setting of obvious capsular rupture in our patient makes the diagnosis of parathyroid carcinoma high likely. The size of the tumor, the infiltrative margin, and the trabecular pattern seen in this tumor are all features of parathyroid carcinoma.

Synchronous parathyroid and nonmedullary thyroid carcinomas are extremely rare with only 15 previous cases reported in literature, and no correlation, up to date, has been discovered between these entities. Twelve patients (84%) were females with relatively young age (mean age of 56 years). Parathyroid carcinoma was active in 13 of the 15 patients described (including our patient):

**TABLE 2** Manifestations suggesting parathyroid carcinoma in primary hyperparathyroidism

| Symptomatic hypercalcemia |
|---------------------------|
| Hypercalcemia: Serum calcium > 3.5 mmol/L |
| High serum PTH level: > 3–10 times above the upper limit of normal |
| Palpable neck mass |
| Simultaneous renal and overt skeletal involvement |
| Coexisting with recurrent severe pancreatitis and anemia |
| Recurrent laryngeal nerve palsy in patients without previous neck surgery |

**FIGURE 1** Surgical specimen. Surgical specimen from the patient (total thyroidectomy + left parathyroidectomy).

**FIGURE 2** Histopathological finding. (A) Parathyroid tumoral nodule with thick capsule with incomplete capsular intrusion (arrow). The tumor cells had abundant cytoplasm with a slightly atypical rounded nucleus. Mitoses were estimated at 5 mitoses/10 CFG (hematoxylin–eosin stain original magnification 40×). (B) Nodular tumor proliferation (parathyroid). In places, there were images of capsular rupture and invasion of peri-glandular adipose tissue with images of lymphatic-vascular tumor emboli (arrows) (hematoxylin–eosin stain original magnification 40×). (C) Papillary microcarcinoma follicular variant. Histological evaluation demonstrating typical features of a papillary carcinoma with a follicular architectural pattern (hematoxylin–eosin stain original magnification 100×).
One published report described an occult parathyroid carcinoma that was found incidentally during total thyroidectomy. The lowest serum calcium level reported in the literature with parathyroid carcinoma has been 12.2 mg/dl, and the lowest reported PTH level associated with parathyroid carcinoma has been 159 pg/ml in conjunction with a serum calcium level of 13.3 mg/dl. Most of the reported cases with active parathyroid tumor had severe hypercalcemia and elevated PTH levels to up 100 times normal levels. The average size of the parathyroid carcinoma was 3.2 cm (maximum >5 cm) with two cases of concomitant hyperplasia or parathyroid adenoma. Synchronous thyroid carcinomas were papillary carcinoma type in 13 patients and follicular type in two cases.

Previous reports have suggested that a history of neck irradiation, long-standing secondary HPT, end-stage renal disease, hereditary HPT-jaw tumor syndrome, and mutations of parafibromin (HRPT2) and cyclin D1 (CCND1) increase the risk of parathyroid carcinomas. Our patient has not been tested for the HRPT2 mutation, and she had no risk factors for parathyroid or thyroid carcinomas.

In case of severe hypercalcemia, parathyroid carcinoma should be considered as possible etiology, and if the peroperative frozen section diagnosis supports the suspicion of parathyroid carcinoma, an en-bloc resection of the parathyroid tumor must be performed. For our patient, an en-block resection was performed with central and lateral cervical lymph node dissection. Postoperatively, the patient has remained normocalcemic with normal PTH levels; however, she needs more follow-up to assume that she does not have any remaining hyperfunctioning gland. In the previous described cases, the follow-up of the patients ranged from 6 months to 6 years: most of the patients remained with normocalcemia, only one case presented persistent hypercalcemia, and another patient died from metastatic parathyroid carcinoma.

4 | CONCLUSION

In conclusion, coexistence of primary hyperparathyroidism due to parathyroid carcinoma along with nonmedullary thyroid carcinoma is extremely rare. Our present case report illustrates crucial points. In fact, although parathyroid carcinoma is an unusual cause of primary hyperparathyroidism, it should be given full attention. The diagnosis is generally established on the conjunction of clinical, radiological, biological, and histological signs.

Moreover, the fortuitous concomitant discovery of papillary thyroid carcinoma emphasizes the importance of knowing this association given the therapeutic implications that result from it.

**AUTHOR CONTRIBUTIONS**

I.B.N, D.K, and M.K involved in data, information collection, manuscript preparation, manuscript review, and literature review. I.R, I.R, S.M, M.B.S, N.M, and K.K involved in study conception and contributed to manuscript draft.

**CONFLICT OF INTEREST**

The authors declare no conflicts of interest.

**DATA AVAILABILITY STATEMENT**

No data were available.

**CONSENT**

Written informed consent was obtained from the patient for the publication of this case report.

**ORCID**

Dayssem Khelifi 🌐 https://orcid.org/0000-0002-9097-7725
Imen Rojbi 🌐 https://orcid.org/0000-0002-4500-9020

**REFERENCES**

1. De Falco N, Santangelo G, Chirico F, et al. Synchronous intrathyroidal parathyroid carcinoma and thyroid carcinoma: case report and review of the literature. **BMC Endocr Disord.** 2021;21:60.
2. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. **Curr Treat Options Oncol.** 2012;13(1):11-23.
3. Al-Kurd A, Mekel M, Mazeh H. Parathyroid carcinoma. **Surg Oncol.** 2014;23(2):107-114.
4. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic feature in 43 patients. **Medicine (Baltimore).** 1992;71:197-205.
5. Lam-Chung CE, Rodríguez-Orihuela DL, Anda González JD, Gamboa-Domínguez A. An unusual simultaneous existence of parathyroid carcinoma and papillary thyroid carcinoma: report and review of literature. **Case Rep Endocrinol.** 2020;2020:2128093.
6. Baek C-O, Kim KH, Song SK. Synchronous parathyroid carcinoma and papillary thyroid carcinoma in a patient with long-standing schizophrenia. **Korean J Intern Med.** 2017;32(6):1104-1107.
7. Kissin M, Bakst H. Co-existing myxedema and hyperparathyroidism; case report. **J Clin Endocrinol Metab.** 1947;7:152-158.
8. Leitha T, Staudenherz A. Concomitant hyperparathyroidism and nonmedullary thyroid cancer, with a review of the literature. **Clin Nucl Med.** 2003;28(2):113-117.
9. Song C, Wang J, Cai X, Gao L. Synchronous parathyroid carcinoma and papillary thyroid carcinoma: a case study and review of literature. **Int J Clin Exp Pathol.** 2016;9(1):302-309.
10. Walgenbach S, Hommel G, Junginger T. Outcome after surgery for primary hyperparathyroidism: ten-year prospective follow-up study. **World J Surg.** 2000;24:564-570.
11. Shane E. Clinical review 122: parathyroid carcinoma. **J Clin Endocrinol Metab.** 2001;86:485-493.
12. Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255-264.
13. Kurita S, Mihashi S, Hirano M, Nakashima T, Tanimura A. Hyperfunctioning parathyroid carcinoma combined with papillary carcinoma of the thyroid gland–report of a case (author’s transl). Nihon Gan Chiryo Gakkai Shi. 1979;14:1127-1135.
14. Christmas TJ, Chapple CR, Noble JG, Milroy EL, Cowie AG. Hyperparathyroidism after neck irradiation. Br J Surg. 1988;75:873-874.
15. Savli H, Sevinc A, Sari R, Ozen S, Buyukberber S, Ertas E. Occult parathyroid carcinoma in a patient with papillary thyroid carcinoma and Hashimoto’s thyroiditis. J Endocrinol Invest. 2001;24:42-44.
16. Bednarek-Tupikowska G, Tolloczko T, Tupikowski W, et al. Coexistence of parathyroid carcinoma and non-medullary carcinoma of the thyroid. Med Sci Monit. 2001;7:448-456.
17. Schoretsanitis G, Melissas J, Kafousi M, Karkavitsas N, Tsiftsis DD. Synchronous parathyroid and papillary thyroid carcinoma: a case report. Am J Otolaryngol. 2002;23:382-385.
18. Lin SD, Tu ST, Hsu SR, Chang JH, Yang KT, Yang LH. Synchronous parathyroid and papillary thyroid carcinoma. J Chin Med Assoc. 2005;68:87-91.
19. Goldfarb M, O’Neal P, Shih JL, Hartzband P, Connolly J, Hasselgren PO. Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr Pract. 2009;15:463-468.
20. Marcy PY, Thariat J, Sudaka A, Poissonnet G. Synchronous parathyroid and papillary thyroid carcinomas. Thyroid. 2009;19:1131-1133.
21. Chaychi L, Belbruno K, Golding A, Memoli V. Unusual manifestation of parathyroid carcinoma in the setting of papillary thyroid cancer. Endocr Pract. 2010;16:664-668.
22. Amoodi HA, Makki FM, Taylor M, Bullock MJ, Hart RD, Trites JR. Synchronous thyroid/parathyroid carcinomas. J Otolaryngol Head Neck Surg. 2010;39(5):E42-E47.
23. Kuzu F, Cinkaya A, Ekici M, Kodaz H, Deger A. Synchronous parathyroid carcinoma and multifocal papillary thyroid carcinoma: a case report. Int J Surg Case Rep. 2017;1(1):49-52.
24. Campennì A, Giovinazzo S, Pignata SA, et al. Association of parathyroid carcinoma and thyroid disorders: a clinical review. Endocrine. 2017;56(1):19-26. doi:10.1007/s12020-016-1147-7
25. Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol. 1999;12:412-416.

How to cite this article: Ben Nacef I, Khelifi D, Kalthoum M, et al. Synchronous parathyroid carcinoma and papillary thyroid carcinoma. Clin Case Rep. 2022;10:e06369. doi:10.1002/ccr3.6369